Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
British Journal of Clinical Pharmacology · 2012 · 1,437 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Calder, P. C. (2012). Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? British Journal of Clinical Pharmacology, 75(3), 645–662. https://doi.org/10.1111/j.1365-2125.2012.04374.x
In text: (Calder, 2012)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are n-3 fatty acids found in oily fish and fish oil supplements. These fatty acids are able to inhibit partly a number of aspects of inflammation including leucocyte chemotaxis, adhesion molecule expression and leucocyte-endothelial adhesive interactions, production of eicosanoids like prostaglandins and leukotrienes from the n-6 fatty acid arachidonic acid, production of inflammatory cytokines and T cell reactivity. In parallel, EPA gives rise to eicosanoids that often have lower biological potency than those produced from arachidonioc acid and EPA and DHA give rise to anti-inflammatory and inflammation resolving resolvins and protectins. Mechanisms underlying the anti-inflammatory actions of n-3 fatty acids include altered cell membrane phospholipid fatty acid composition, disruption of lipid rafts, inhibition of activation of the pro-inflammatory transcription factor nuclear factor kappa B so reducing expression of inflammatory genes, activation of the anti-inflammatory transcription factor NR1C3 (i.e. peroxisome proliferator activated receptor γ) and binding to the G protein coupled receptor GPR120. These mechanisms are interlinked. In adult humans, an EPA plus DHA intake greater than 2 g day⁻¹ seems to be required to elicit anti-inflammatory actions, but few dose finding studies have been performed. Animal models demonstrate benefit from n-3 fatty acids in rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and asthma. Clinical trials of fish oil in patients with RA demonstrate benefit supported by meta-analyses of the data. Clinical trails of fish oil in patients with IBD and asthma are inconsistent with no overall clear evidence of efficacy.
Related papers
- Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor1992
- Adherence to a Mediterranean Diet and Survival in a Greek Population2003
- Dietary pattern analysis: a new direction in nutritional epidemiology2002
- Fish Consumption, Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Disease2002
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia2018
Metadata from OpenAlex (CC0). Citations are generated from the published record.